> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Firms Seek EUA for Omicron Vaccine in Young Children
- URL: https://www.fdaweb.com/firms-seek-eua-for-omicron-vaccine-in-young-children/
- Published: 2022-12-05T12:00:00.000Z
- Updated: 2026-09-14T18:08:32.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5153315

Pfizer and BioNTech have submitted an application seeking an emergency use authorization for their Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine as a third dose in the primary series for protecting children aged six months through four years of age. If authorized, eligible children would receive a primary series consisting of two doses of the original Pfizer-BioNTech Covid-19 vaccine followed by a third dose of the Omicron BA.4/BA.5-adapted bivalent vaccine. The Omicron bivalent vaccine is currently authorized as a booster dose for ages five years and older in the U.S.